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PHAR M ACEUTIC AL STABILIZ ATION OF ABDOMINAL AORTIC ANEURYSM S
Changing its natural history
Vivianne B. C. Kokje
1. The optimism for pharmaceutical AAA stabilization is based on successful inhibition of AAA growth in 
animal models and case series, and not on large randomized controlled trials. – dit proefschrift 
2. Neutrophil influx is a key perpetuator the chronic inflammation in AAA disease and provides a highly 
promising pharmaceutical target for AAA stabilization. – dit proefschrift
3. Despite extremely high levels of IL6 in the AAA vessel wall, IL6 does not play a key role in AAA 
progression. – dit proefschrift
4. Enrichment of adipocyte-related genes and pathways in ruptured AAA versus non-ruptured controls 
implies an association between fatty degeneration of the AAA wall and AAA rupture. – dit proefschrift 
5. An atherosclerotic aneurysm of the aorta is a misnomer 
6. AAA diameter remains the most widely used marker of AAA progression. However, as the mean 
AAA growth rates are within the inter-observer measurements error/variation for ultrasound, newer 
imaging assessments, such as volume measurements, biomechanical analyses, and functional and 
molecular imaging, as well as circulating biomarkers, have potential to add important information 
about AAA progression –J. Golledge [Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):236-44.]
7. The angiotensin II model reflects a process of aortic dissection rather than AAA disease – 
A. Daugherty PhD, University of Kentucky. [Founder of the Angiotensine 2 AAA model and Cardiovasc 
Res 2015; 105: 213-22.]
8. Smoking cessation should always be pursued, regardless of other therapies. – F.A. Lederle MD PhD, 
University of Minnesota School of Medicine [Circulation 2011 Sep 6;124(10):1097-9.]
9. Extreme pricing in the pharmaceutical market indicates that there is a discrepancy between their 
market-driven policies and their original incentives for innovation 
10. Excellent interdisciplinary collaboration is needed in healthcare, however the rivalry and competition 
between departments, hospitals and countries holds back global healthcare progression
11. Whatever you are, be a good one – Abraham Lincoln (1809 –1865, 16th president of the United States of 
America) [A. Lincoln: A Biography by Ronald C. White Jr.]
